The U.S. Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery.
Sep 10, 2013
0
0
(Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. ...
Jun 4, 2013
0
0
A new cervical cancer drug offers the first good hope of extending life for women with advanced stages of the disease, according to a study published Sunday.
Jun 2, 2013
0
0
A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.
Jun 1, 2013
0
1
(Medical Xpress)—The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR ...
Apr 10, 2013
0
1
(HealthDay)—In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.
Feb 26, 2013
0
0
(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, ...
Feb 1, 2013
0
0
(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according to a study ...
Dec 12, 2012
0
0
(Medical Xpress)—With the perspective of a scientist trained in acupuncture, Alison Adams is well positioned to explain why placebos may be misunderstood—and why they should be understood in the first place.
Nov 2, 2012
0
0
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.
Jul 13, 2012
0
0
